News | EP Lab | August 03, 2021

Patients With Atrial Fibrillation and Heart Failure Benefit From Early Rhythm Control

EP lab ablation catheter. #HRS21 #HRS2021

August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm control therapy is associated with clinical benefit in patients with heart failure and recently diagnosed atrial fibrillation (AF). The new findings were presented by Dr. Andreas Rillig, University Heart Center Hamburg, Germany, at the Heart Rhythm Society (HRS) annual meeting. 

The EAST – AFNET 4 is an investigator initiated trial (IIT) that compared two different treatment strategies in atrial fibrillation.[1] The EAST – AFNET 4 trial tested whether an early, comprehensive rhythm control therapy can prevent adverse cardiovascular outcomes in patients with AF compared to usual care.

A total of 2,789 patients with early AF (diagnosed less than a year ago) and at least two cardiovascular conditions (approximating a CHA₂DS₂-VASc score >=2) were enrolled by 135 sites in 11 countries during 2011 to 2016. Patients were randomized 1:1 to early rhythm control therapy or usual care, stratified by sites. Patients in both groups received guideline-recommended treatment for underlying cardiovascular conditions, anticoagulation, and rate control.

All patients in the early rhythm control group received anti-arrhythmic drugs or catheter ablation after randomization (chosen by the local study teams). Rhythm control therapy was escalated with AF ablation and/or anti-arrhythmic drugs when recurrent AF was documented clinically or by ECG, including monitoring with patient-operated ECG devices.

Patients in the usual care group were initially managed with rate control. Rhythm control therapy was only used to improve atrial fibrillation-related symptoms despite optimal rate control, following current guidelines.

About the Atrial Fibrillation NETwork (AFNET)

The Atrial Fibrillation NETwork is an interdisciplinary research network comprising scientists and physicians from hospitals and practices dedicated to improving the management of atrial fibrillation through coordinated research in Germany, Europe, and worldwide. Its main objective is to conduct high quality investigator-initiated clinical trials and registries on a national and international level. The AFNET continues the long-term activities of the network which has been funded by the German Federal Ministry of Research and Education over a decade. Since January 2015, specific projects and infrastructures of the AFNET are funded by the German Centre for Cardiovascular Research (DZHK).

Find additional HRS 2021 late breaking trials

Find more EP device news

Find more HRS 2021 conference news

 

Reference:

1. Paulus Kirchhof, A. John Camm, Andreas Goette, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med 2020; 383:1305-1316
DOI: 10.1056/NEJMoa2019422.

Related Content

News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
News | Ablation Systems

May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an ...

Home May 14, 2019
Home
News | Ablation Systems

May 13, 2019 — Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands ...

Home May 13, 2019
Home
Subscribe Now